Positive CHMP opinion paves way for Lundbeck's Vyepti in Europe
Lundbeck's migraine treatment Vyepti should be approved in Europe, according to the EMA's expert committee (CHMP), which evaluated the pharmaceutical company's marketing application during its November meeting.
BY ELIZABETH MØNSTED JOHANSEN, translated by daniel pedersen
Lundbeck is a huge step closer to realizing its launch of the migraine drug Vyepti on the European market.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
